Trial Profile

Phase I trial of HTL-0022562 in healthy volunteers for the treatment of migraine

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HTL 0022562 (Primary)
Indications Migraine
Focus Adverse reactions
Sponsors Nxera Pharma; Sosei

Most Recent Events

01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
19 Mar 2018 New trial record
13 Mar 2018 According to a Sosei media release, earlier the first dosing in the Phase I clinical trial in healthy volunteers was expected in late 2018. Sosei will provide an update about the trial later this year

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com